Ceftriaxone
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Ceftriaxone
- Pharmacist Assessment Report
- Ceftriaxone: Third-generation cephalosporin (beta-lactam antibiotic) → polyclonal hyperviscosity syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ceftriaxone: Third-generation cephalosporin (beta-lactam antibiotic) → polyclonal hyperviscosity syndrome
One-Sentence Summary
Ceftriaxone is an injectable beta-lactam antibiotic that acts on bacterial cell wall synthesis. The TxGNN model predicts it may be relevant to polyclonal hyperviscosity syndrome, but there are no clinical trials and no publications supporting this prediction, so it rests on the model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9939 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Ceftriaxone is known to be a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.
Polyclonal hyperviscosity syndrome is a haematological/immunological condition with no bacterial target, so no mechanistic link to ceftriaxone has been identified. The high prediction score is a model output only. It should not be read as a sign of clinical benefit, and it has no supporting trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11169W | Ceftriaxone Viatris | Powder for injection 2 g (as sodium) | Indication text not recorded in the local data |
Safety Considerations
- Drug Interactions: The interaction search returned 100 records. The main ones flagged as Major are:
- Calcium chloride
- Calcium glucoheptonate
- Calcium gluconate
Moderate interactions include kanamycin, neomycin, streptomycin and picosulfuric acid.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications and no plausible mechanism, since the condition has no bacterial target. Evidence is at the model-prediction level only (L5).
To proceed, the following is needed:
- Any study that directly examines ceftriaxone in polyclonal hyperviscosity syndrome
- A plausible mechanistic rationale
- Mechanism of action data and warnings and contraindications from the TGA Product Information
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.